Importantly, targeting hormonal FABP4, either through genetic ablation or monoclonal antibody therapy, has been proven to protect against or reverse diabetes in preclinical models of genetic or diet-induced obesity (5, 9, 10). Here, FABP4 is linked to diabetes mellitus.